BPC-157
Experimental peptide studied predominantly in preclinical models involving tissue repair and other biological processes.
Very limited human evidenceExplore this ingredient →← All stacks & combinationsINGREDIENT INGREDIENT POPULAR GOALS THE COMMUNITY RATIONALE THE OPEN QUESTION BPC-157 TB-500 Human report · related pairing Research review · individual ingredient Regulatory guidance · ingredient safety
Community combination
Wolverine Stack
Known as the Wolverine stack, BPC-157 and TB-500 are commonly discussed together for tendon, ligament and soft-tissue recovery. Research on the combination itself is still limited.
Recovery & Healing
01
THE BUILDING BLOCKS
What’s in it?
TB-500
Thymosin beta-4-related research compound with predominantly preclinical evidence.
Limited evidenceExplore this ingredient →The ingredients listed here do not specify a particular product or mixing ratio. Pre-mixed products may differ from the formulations used in research.
02
PEOPLE & EXPERIENCE
Why this combination is discussed
Known as the Wolverine stack, BPC-157 and TB-500 are commonly discussed together for tendon, ligament and soft-tissue recovery. Research on the combination itself is still limited.
Recovery & Healing
Commonly discussed for tendon, ligament and soft-tissue recovery, this pairing brings together BPC-157 and TB-500.
Both ingredients are discussed in tissue-repair research. Whether combining them improves healing remains an open question.
Community experience can explain why a pairing has become popular. It cannot show whether the ingredients work better together or whether a mixed product is stable, accurately dosed or safe.
03
THE REASON FOR INTEREST
Why people combine them
Commonly discussed for tendon, ligament and soft-tissue recovery, this pairing brings together BPC-157 and TB-500.
How their research overlaps
Both ingredients are discussed in tissue-repair research. Whether combining them improves healing remains an open question.
The individual profiles explain each ingredient’s potential benefits and research. Even when their effects seem complementary, studies are needed to find out whether using them together adds a benefit.
04
Small human report on a related pairingWHAT THE RESEARCH CAN SUPPORT
Evidence for this combination
A small report on knee pain looked back at patients treated with BPC-157, including some who also received thymosin-beta-4 (TB4). This offers limited information about a related pairing, but it was not a controlled trial of the Wolverine stack.
Products sold as TB-500 may differ from the TB4 used in the report. Differences in the products, how they were given and which patients were included make it difficult to draw wider conclusions. The report cannot show whether combining them works better.
Explore the sources below ↓05
RESEARCH & COMMUNITY CONTEXT
Doses & duration
Start with each ingredient—not an invented combined dose
No validated combined starting dose exists. The cards below preserve the practical structure people look for while keeping each ingredient’s reported pattern separate.
Anecdotal / unvalidated
- Starting point discussed
- Online communities discuss many different starting amounts and routes; there is no accepted clinical starting dose.
- Duration / cycle
- Short 'cycles' are commonly discussed, often framed around injury recovery rather than chronic treatment.
- Continuation / break
- Maintenance use is discussed online, but no clinically validated maintenance schedule has been identified.
Community-described only
- Starting point discussed
- Online starting-dose protocols vary widely; the site does not convert those patterns into a validated clinical starting dose.
- Duration / cycle
- Cycle-based use is commonly discussed in peptide communities, particularly around injury and soft-tissue recovery.
- Continuation / break
- No validated TB-500 maintenance schedule has been established in human research.
Using two ingredients in the same period and mixing them in one vial or syringe are different questions. Separate schedules cannot establish compatibility, interactions or a safe combined total.
06
WHAT REMAINS UNCERTAIN
Safety & uncertainties
- The combination needs its own safety research, including possible interactions and side effects.
- What a product contains, how it is made and how it is used all matter. Products sold under the same name may differ.
- A clinician can assess how existing medicines or health conditions affect the risks. These pages provide general information, not personal treatment advice.
07
FOLLOW THE EVIDENCE
Sources & search record
Last source check: 14 September 2026
Each link explains what it covers: the combination itself, an individual ingredient or safety information. A trial record and a paper can describe the same study.
Lee et al., 2021 — intra-articular BPC-157 knee-pain report ↗
A look back at patients who received BPC-157 alone or with TB4. It does not show that the pairing works better or that commercial TB-500 blends are equivalent.
Emerging Use of BPC-157 in Orthopaedic Sports Medicine (2025) ↗
A review of BPC-157 research, mostly from lab and animal studies. It brings existing findings together rather than testing a stack.
FDA: peptide compounding safety concerns ↗
Safety information about individual ingredients, rather than the combination. This is US guidance, not a statement of UK legal status.
About this search
We used targeted web searches for ingredient pairs, including searches focused on PubMed and ClinicalTrials.gov. We followed relevant papers, research reviews and FDA safety information, checking whether the ingredients were actually given together and how they were used. Some full papers were unavailable, so we relied on their published summaries. Web searches can miss studies: this was a targeted source check, not an exhaustive or systematic review, a clinical assessment or a review of UK regulation. The links below let you explore further; search results are not evidence on their own.
Search terms used
- BPC-157 thymosin beta 4 knee pain Intra-Articular Injection retrospective 2021
- site:clinicaltrials.gov "BPC-157" ("TB-500" OR "thymosin beta" OR "GHK-Cu" OR "KPV")
- BPC-157 systematic review orthopaedic 2025
Search for these ingredients together:
Studies may use different names for the same ingredient. The search terms above show which alternatives we checked. Community experiences can explain interest in a stack, but we did not count anecdotes or seller claims as clinical studies.